3Kintzel PE. Anticancer drug - reduced kidney disorders [ J ]. Drug Saf,2001,24 ( 1 ) : 19 - 38.
4Hartmann JT, Lipp HE. Toxicity of platinum compounds [ J ]. Expert Opin Pharmacother,2003,4 (6) :$89 - 901.
5Hartmann Jr. Long - term effects of platin and anthraeyeline erivatives and possible prevention strategies [ J ]. Front Radiat Ther Oncol,2002,37( 1 ) :92 - 100.
6Mohammadianpanah M, Omidvari S, Mosalaei A, et al. Cisplatin - induced hypokalemic paralysis [ J]. Clin Ther, 21304,26 (8) : 1320 - 1323.
7Panichpisal K, Angulo - Pemett F, Selhi S, et al. Gitelman - like syndrome after cisplatin therapy:a case report and literature review [J]. BMC Nephro,2006,7(1 ) :10.
8Lajer H, Daugaard G. Cisplatin and hypomagnesemia [ J ]. Cancer Treat Rev, 1999,25 ( 1 ) :47 - 58.
9Dai LJ, Ritchie G, Kerstan D, et al. Magnesium transport in the renal distal convoluted tubule [J].Physiol Rev,21301,81(1):51 -84.
10Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin [ J 1. Gynecol Oncol, 1993,50(2) :147 - 158.
